Is ivvd a buy

**Invivyd (IVVD) appears to be a promising investment opportunity**, and here's why:

1. **Strong Financial Performance and Growth Prospects**: Invivyd has achieved significant revenue growth, with a 48% increase in Q4 2024 net product revenue compared to Q3 2024. The full-year 2024 net product revenue totaled $25.4 million. This growth trajectory indicates a strong market demand for their products.
2. **Positive Earnings Surprise**: The company reported a quarterly loss of $0.15 per share, which was better than the Zacks Consensus Estimate of a loss of $0.25. This represents a 40% earnings surprise, indicating efficient cost management and operational effectiveness.
3. **Consistent Product Efficacy**: Invivyd's monoclonal antibody PEMGARDA™ has shown consistent in vitro neutralization against SARS-CoV-2 variants, including the dominant LP.8.1. This stability in efficacy is a critical factor for a company developing treatments for viral diseases.
4. **Analyst Confidence and Price Target**: The consensus rating for Invivyd is a "Strong Buy" with an average price target of $9.38, suggesting that analysts believe the stock has potential for growth. Additionally, Wall Street analysts have set a higher price target of $10.00, indicating optimism about the company's future.

5. **Technical Indicators Supportive of a Buy Signal**: Technical indicators such as the Relative Strength Index (RSI) and the Moving Average Convergence Divergence (MACD) are at levels that typically suggest a stock is neither overbought nor oversold and that a trend could be emerging